Roger Abounader

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9132673/publications.pdf

Version: 2024-02-01

74	5,519	76294 40	82499 72
papers	citations	h-index	g-index

103	103	103	7842
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and Is Down-regulated in Glioblastoma. Cancer Research, 2008, 68, 3566-3572.	0.4	705
2	MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes. Cancer Research, 2009, 69, 7569-7576.	0.4	566
3	microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle, 2010, 9, 1031-1036.	1.3	289
4	Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-Oncology, 2005, 7, 436-451.	0.6	269
5	The p53 Pathway in Glioblastoma. Cancers, 2018, 10, 297.	1.7	232
6	The Neuronal MicroRNA miR-326 Acts in a Feedback Loop with Notch and Has Therapeutic Potential against Brain Tumors. Journal of Neuroscience, 2009, 29, 15161-15168.	1.7	211
7	In vivo targeting of SF/HGF and câ€met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB Journal, 2002, 16, 1-16.	0.2	159
8	Oncogenic effects of miR-10b in glioblastoma stem cells. Journal of Neuro-Oncology, 2013, 112, 153-163.	1.4	151
9	Targeting the c-Met Pathway Potentiates Glioblastoma Responses to Î³-Radiation. Clinical Cancer Research, 2005, 11, 4479-4486.	3.2	117
10	BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y2 receptor antagonist. British Journal of Pharmacology, 2000, 129, 1075-1088.	2.7	111
11	microRNA-148a Is a Prognostic oncomiR That Targets MIG6 and BIM to Regulate EGFR and Apoptosis in Glioblastoma. Cancer Research, 2014, 74, 1541-1553.	0.4	106
12	The Scatter Factor/Hepatocyte Growth Factor: c-Met Pathway in Human Embryonal Central Nervous System Tumor Malignancy. Cancer Research, 2005, 65, 9355-9362.	0.4	103
13	Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Laboratory Investigation, 2005, 85, 1457-1470.	1.7	102
14	Novel Anti-Apoptotic MicroRNAs 582-5p and 363 Promote Human Glioblastoma Stem Cell Survival via Direct Inhibition of Caspase 3, Caspase 9, and Bim. PLoS ONE, 2014, 9, e96239.	1.1	95
15	The role of microRNAs in glioma initiation and progression. Frontiers in Bioscience - Landmark, 2012, 17, 700.	3.0	94
16	Diacylglycerol Kinase Î± Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers. Cancer Discovery, 2013, 3, 782-797.	7.7	93
17	PTEN Has Tumor-Promoting Properties in the Setting of Gain-of-Function p53 Mutations. Cancer Research, 2008, 68, 1723-1731.	0.4	92
18	Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor. Molecular Cancer Research, 2008, 6, 139-150.	1.5	85

#	Article	IF	Citations
19	Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y₁ antagonist BIBP 3226. British Journal of Pharmacology, 1995, 116, 2245-2250.	2.7	82
20	MicroRNA-608 and MicroRNA-34a Regulate Chordoma Malignancy by Targeting EGFR, Bcl-xL and MET. PLoS ONE, 2014, 9, e91546.	1.1	80
21	Targetable T-type Calcium Channels Drive Glioblastoma. Cancer Research, 2017, 77, 3479-3490.	0.4	79
22	A New lncRNA, APTR, Associates with and Represses the CDKN1A/p21 Promoter by Recruiting Polycomb Proteins. PLoS ONE, 2014, 9, e95216.	1.1	76
23	Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. Clinical Cancer Research, 2017, 23, 6958-6968.	3.2	74
24	Signaling pathways in medulloblastoma. Journal of Cellular Physiology, 2008, 217, 577-583.	2.0	72
25	Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis. PLoS Medicine, 2016, 13, e1002192.	3.9	71
26	Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Laboratory Investigation, 2008, 88, 98-111.	1.7	61
27	Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma. Cancer Research, 2019, 79, 5218-5232.	0.4	57
28	Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Research, 2003, 63, 2990-6.	0.4	55
29	Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma. Cancers, 2017, 9, 87.	1.7	53
30	The roles of viruses in brain tumor initiation and oncomodulation. Journal of Neuro-Oncology, 2011, 105, 451-466.	1.4	52
31	Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro-Oncology, 2018, 20, 192-202.	0.6	52
32	Regulation of c-Met-dependent gene expression by PTEN. Oncogene, 2004, 23, 9173-9182.	2.6	51
33	An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 28-35.	0.9	50
34	Expression of Neuropeptide Y Receptors mRNA and Protein in Human Brain Vessels and Cerebromicrovascular Cells in Culture. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 155-163.	2.4	49
35	XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs: the Investigational Drugs Journal, 2010, 13, 112-21.	0.7	49
36	Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Molecular Cancer Therapeutics, 2009, 8, 376-385.	1.9	46

#	Article	IF	Citations
37	A Novel PTEN/Mutant p53/c-Myc/Bcl-XL Axis Mediates Context-Dependent Oncogenic Effects of PTEN with Implications for Cancer Prognosis and Therapy. Neoplasia, 2013, 15, 952-965.	2.3	46
38	Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Research, 2018, 78, 4360-4369.	0.4	46
39	microRNA-34a promotes DNA damage and mitotic catastrophe. Cell Cycle, 2013, 12, 3500-3511.	1.3	45
40	Targeting MET for glioma therapy. Neurosurgical Focus, 2014, 37, E10.	1.0	45
41	Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Review of Anticancer Therapy, 2009, 9, 235-245.	1.1	43
42	A miR-297/hypoxia/DGK-Î± axis regulating glioblastoma survival. Neuro-Oncology, 2013, 15, 1652-1663.	0.6	42
43	Patterns of Capillary Plasma Perfusion in Brains of Conscious Rats During Normocapnia and Hypercapnia. Circulation Research, 1995, 76, 120-126.	2.0	38
44	Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. Clinical Cancer Research, 2003, 9, 4274-81.	3.2	38
45	CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia, 2004, 45, 297-306.	2.5	36
46	Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clinical Cancer Research, 2019, 25, 663-673.	3.2	35
47	A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma. Nature Communications, 2020, 11, 3457.	5.8	35
48	MicroRNA-29a inhibits glioblastoma stem cells and tumor growth by regulating the PDGF pathway. Journal of Neuro-Oncology, 2019, 145, 23-34.	1.4	33
49	Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma. PLoS ONE, 2015, 10, e0134426.	1.1	30
50	Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition. Clinical Cancer Research, 2013, 19, 1433-1444.	3.2	29
51	Regulatory factor X1 is a new tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma. Neuro-Oncology, 2014, 16, 1078-1085.	0.6	28
52	Glioma Inhibition by HGF/NK2, an Antagonist of Scatter Factor/Hepatocyte Growth Factor. Biochemical and Biophysical Research Communications, 2000, 273, 287-293.	1.0	23
53	370â€ƒMagnetic Resonance-Guided Focused Ultrasound Delivery of Polymeric Brain-Penetrating Nanoparticle MicroRNA Conjugates in Glioblastoma. Neurosurgery, 2016, 63, 210.	0.6	22
54	Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2018, 1861, 983-995.	0.9	21

#	Article	IF	Citations
55	HGF/MET Signaling in Malignant Brain Tumors. International Journal of Molecular Sciences, 2020, 21, 7546.	1.8	21
56	Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy. Molecular Cancer Therapeutics, 2012, 11, 288-297.	1.9	20
57	p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia, 2018, 66, 999-1015.	2.5	19
58	Noncoding RNAs in Glioblastoma. , 0, , 95-130.		19
59	The tumor-suppressive long noncoding RNA DRAIC inhibits protein translation and induces autophagy by activating AMPK. Journal of Cell Science, 2021, 134, .	1.2	18
60	Scatter factor/hepatocyte growth factor gene transfer increases rat bloodâ€“glioma barrier permeability. Brain Research, 1999, 833, 173-180.	1.1	16
61	Ethanol Extract of Securidaca longipedunculata Induces Apoptosis in Brain Tumor (U87) Cells. BioMed Research International, 2019, 2019, 1-5.	0.9	11
62	Insight into the role of microRNAs in brain tumors (Review). International Journal of Oncology, 2011, 40, 605-24.	1.4	10
63	MicroRNA 3928 Suppresses Glioblastoma through Downregulation of Several Oncogenes and Upregulation of p53. International Journal of Molecular Sciences, 2022, 23, 3930.	1.8	8
64	Design and Expression of Chimeric U1/Ribozyme Transgenes. , 2004, 252, 209-220.		7
65	The p53â€“microRNA-34a axis regulates cellular entry receptors for tumor-associated human herpes viruses. Medical Hypotheses, 2013, 81, 62-67.	0.8	7
66	Activities of Some Medicinal Plants on the Proliferation and Invasion of Brain Tumor Cell Lines. Advances in Pharmacological and Pharmaceutical Sciences, 2020, 2020, 1-7.	0.7	6
67	MicroRNAs: Key Regulators in Lung Cancer. MicroRNA (Shariqah, United Arab Emirates), 2021, 10, 109-122.	0.6	6
68	Transcribed Ultraconserved Regions in Cancer. Cells, 2022, 11, 1684.	1.8	6
69	When tumor cells make blood vessels: implications for glioblastoma therapy. Future Oncology, 2011, 7, 841-843.	1.1	5
70	Gene expression in mouse muscle over time after nickel pellet implantation. Metallomics, 2020, 12, 528-538.	1.0	5
71	The blood-brain barrier limits the therapeutic efficacy of antibody-drug conjugates in glioblastoma. Neuro-Oncology, 2021, 23, 1993-1994.	0.6	4
72	A new practical and versatile mouse model of proneural glioblastoma. Neuro-Oncology, 2018, 20, 299-301.	0.6	2

#	Article	IF	Citations
73	A new class of radiosensitizers for glioblastoma. Oncotarget, 2021, 12, 1199-1200.	0.8	0
74	CSIG-01. IDENTIFICATION OF PATHOGENESIS-RELEVANT microRNAs IN BRAIN METASTASIS. Neuro-Oncology, 2020, 22, ii27-ii27.	0.6	0